New lipid nanoparticle design improves precision of mRNA vaccine delivery
Why it matters: More efficient mRNA vaccines mean stronger immunity with fewer side effects, benefiting global health.
- Penn Engineers redesigned lipid nanoparticles (LNPs) to improve mRNA vaccine delivery.
- The new LNP design specifically targets lymph nodes, crucial for immune response activation.
- Off-target delivery to the liver is significantly reduced, addressing a common challenge in current mRNA vaccine technology.
Penn Engineers have innovated a new lipid nanoparticle (LNP) design for mRNA vaccines, enhancing their precision by directing them to lymph nodes and minimizing off-target delivery to the liver. This breakthrough promises to significantly improve vaccine efficiency, potentially leading to stronger immune responses with lower doses.
